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Abstract 
Background: Patient reported outcome measurements (PROMs) are emerging as an important component of 
patient management in the cancer setting, providing broad perspectives on patients’ quality of life and experience. 
The use of PROMs is, however, generally limited to the context of randomised control trials, as healthcare services 
are challenged to sustain high quality of care whilst facing increasing demand and financial shortfalls. We performed 
a systematic review of the literature to identify any oncological benefit of using PROMs and investigate the wider 
impact on patient experience, in cancers of the pelvic abdominal cavity specifically.
Methods: A systematic review of the literature was conducted using MEDLINE (Pubmed) and Ovid Gateway (Embase 
and Ovid) until April 2020. Studies investigating the oncological outcomes of PROMs were deemed suitable for 
inclusion.
Results: A total of 21 studies were included from 2167 screened articles. Various domains of quality of life (QoL) were 
identified as potential prognosticators for oncologic outcomes in cancers of the pelvic abdominal cavity, independent 
of other clinicopathological features of disease: 3 studies identified global QoL as a prognostic factor, 6 studies identi‑
fied physical and role functioning, and 2 studies highlighted fatigue. In addition to improved outcomes, a number of 
included studies also reported that the use of PROMs enhanced both patient‑clinician communication and patient 
satisfaction with care in the clinical setting.
Conclusions: This review highlights the necessity of routine collection of PROMs within the pelvic abdominal cancer 
setting to improve patient quality of life and outcomes.
Keywords: Patient reported outcome measurements, Health related quality of life, Prognostic factors, Overall survival, 
Pelvic abdominal cancers
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Introduction
The incidence of cancers of the pelvic abdominal cav-
ity (broadly urological, gynaecological, colorectal, gas-
tric, hepatic and pancreatic tumour types) is increasing 
as population life-expectancy increases [1]. As of 2018, 
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prostate and bowel were two of the most commonly 
diagnosed cancers worldwide and, with treatments 
emerging and evolving, survival rates for the majority of 
tumour types continue to increase [2]. Such increasing 
survival rates place huge importance on ensuring ade-
quate levels of quality of life for patients, as life-extend-
ing cancer treatment regimens may result in increased 
symptom burden and decreased physical and emotional 
functioning.
Patient reported outcome measures (PROMs) are 
emerging as an important component for patient man-
agement in the cancer setting. PROMs are standardised 
and validated self-complete instruments which broadly 
provide patient perspective on domains relating to qual-
ity of life, symptom management, patient functioning 
and patient satisfaction with care or perceptions of care 
[3, 4]. Empirical evidence supports the use of PROMs in 
the clinical setting to identify patient concerns, enhance 
patient-clinician communication and improve patient 
satisfaction with care in the clinical setting [5, 6]. The 
widespread use of PROMs routinely is, however, limited, 
with the majority of use occurring within randomised 
control trials (RCTs) where PROMs are used to monitor 
health status and quality of life before, during and after 
experimental treatments. Additionally, PROMs are used 
in this setting to assess whether the survival benefits of 
a specific treatment may outweigh any potential side 
effects or for choosing between treatment options which 
offer similar survival benefit [7–9].
The use of PROMs in routine clinical practice is limited 
as healthcare services are challenged to sustain high care 
quality, whilst also facing increased demand and financial 
shortfalls [10]. Moreover, there exists a lack of established 
standard on what PROMs should be utilised in which set-
ting and how benefit should be measured [11]. Indeed, 
despite the well-known benefits of PROMs in terms 
of quality of life, less is understood about the potential 
oncological benefits of utilising PROMs routinely in the 
clinical setting. Emerging evidence suggests a potential 
role for PROMs as independent prognostic tools which, 
when used alongside clinicopathological information, 
may provide clinicians with a more valid and comprehen-
sive understanding of patient disease [12, 13]. A deeper 
understanding of this potentially prognostic function is 
imperative in order to develop a rationale for the wide-
spread implementation of routine collection of PROMs 
within the clinical setting.
We therefore sought to systematically review the litera-
ture to determine current understanding of the potential 
prognostic role of PROMs, with reference to tumours 
of the pelvic-abdominal cavity specifically. Studies were 
critically appraised to identify any measurable oncologic 
benefit and are described using a narrative presentation.
Methods
Search strategy and inclusion criteria
The research question, search strategy, and inclusion and 
exclusion criteria were developed prior to commence-
ment of literature searching in April 2020. Relevant stud-
ies were identified by conducting searches of Medline 
(Pubmed) and Ovid Gateway (Embase and Ovid) using 
the listed search terms from inception until April 2020. 
A comprehensive set of search terms was compiled and is 
included as a supplement (Additional file 1: Appendix A). 
After searching, the list of returned articles was further 
filtered to include only articles published in the English 
language and studies referring to humans alone. Refer-
ence lists of included articles were also checked for addi-
tional relevant literature.
The full inclusion and exclusion criteria are presented 
in Table  1. The following inclusion criteria was utilised: 
a randomised control trial, an observational study or 
an original article, written in the English language, and 
investigating the oncological outcomes of PROMs in 
patients with urological, gynaecological, colorectal, pan-
creatic, gastric or hepatic tumour types. Commentaries, 
author’s replies, reviews, supplements, editorials and 
systematic reviews were excluded. Studies that included 
patients with cancers other than pelvic abdominal 
tumours were included on the condition that the relevant 
pelvic abdominal cancer data could be isolated.
All duplicates were removed, and articles were 
reviewed by title, abstract and full text by the first author 
(CM). A second author (MVH) subsequently reproduced 
the results of the search strategy before independently 
undertaking screening of all articles included for full 
text review. In case of disagreement, a third independent 
reviewer (TGU) was consulted to confirm the final list of 
included studies. Management of the screening process 
occurred using Microsoft Excel.
Quality assessment
Initially, the quality of each study was assessed by CM 
using quality assessment tools developed by the Joanna 
Briggs Institute (JBI) (http://joann abrig gs.org/resea rch/
criti cal-appra isal-tools .html). The JBI have developed 
various tools for assessing the quality of quantitative 
studies that are appropriate for use in systematic reviews 
to appraise questions of aetiology and risk. The purpose 
of such appraisals is to broadly assess the methodological 
quality of a study and to determine the extent to which 
each study addresses the possibility of bias in its design, 
conduct and analysis. Owing to the varying design of 
the included studies, JBI critical appraisal checklists for 
cohort studies, randomised control trials and case series 
were utilised. The appraisals are included separately as 
Additional file  1: Appendix B1, B2 and B3. Following 
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critical appraisal by CM, a second author (MVH) inde-
pendently assessed the quality of each included study 
using the JBI critical appraisal tools. Each of the studies 
were subsequently discussed to identify any differences 
in opinion with consultation from a third author (TGU).
Results
Evidence synthesis
As detailed in the PRISMA flow diagram (Fig.  1), the 
search strategy identified 2191 articles. Following the 
removal of 24 duplicates, and using the inclusion crite-
ria outlined above, 2167 articles were screened by title. 
A further 228 records subsequently underwent abstract 
review before 43 were assessed based on the full text. 
Overall, 21 articles were deemed suitable for inclu-
sion. Full details of the included studies are presented in 
Table 2.
Of the 21 included studies, 7 were randomised control 
trials and 14 were observational in design. The articles 
were published between 1997 and 2018 and included 
sample sizes ranging from 47 patients to 2603. Seven of 
the studies were conducted on patients with pancreatic 
cancer; 6 on patients with a diagnosis of colorectal can-
cer; 5 on prostate cancer patients; 4 on urological cancers 
(including bladder and renal cancers); 3 on gynaecologi-
cal cancers and 2 on gastric cancer patients. Although the 
studies were conducted worldwide, a large proportion 
(10/21) were published in the United States. The treat-
ment setting of each included study also differed; 5 of 
the studies included patients undergoing chemotherapy 
regimens, 3 were conducted in the surgical setting, one 
study included survivors only and two studies included 
patients receiving targeted therapy or hormonal therapy/
radiotherapy.
Data presentation
Due to a lack of study homogeneity relating specifically 
to the patient reported outcome measurements utilised, 
quantitative synthesis was not viable and hence results 
are presented in a narrative style.
Randomised control trials
Of the seven RCTs included [14–20], two were interven-
tions implemented in pancreatic cancer populations [15, 
16], two were undertaken in a colorectal cancer setting 
[14, 17], one in bladder cancer [19], one in gastric can-
cer [18] and one in prostate cancer [20]. Two studies 
were based on the same RCT (Clinical Outcomes Surgi-
cal Therapy trial NCCTG 93-46-53), but investigated the 
prognostic significance of measuring baseline patient 
reported outcomes (PROs) in slightly different capaci-
ties [14, 17]. These two studies utilised results from a 
surgical RCT where the intervention compared open ver-
sus laparoscopic techniques in terms of post-operative 
Table 1 Inclusion and exclusion criteria for screening
Inclusion criteria Exclusion criteria
Peer reviewed paper Non full text articles





 Any urological cancer
 Any gynaecological cancer
 Any colorectal cancer
 Any gastric cancer
 Any hepatic cancer
 Any pancreatic cancer
Studies in which data pertaining to any of 







 Randomised control trial
 Prospective cohort
 Non‑randomised control trial
 Cross sectional
Variables examined:
 Prognostic potential of PROMs
 Specific QoL instruments with prognostic potential
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complications and patient outcomes. Both studies used 
the Symptom Distress Scale and QOL Index recorded 
preoperatively to demonstrate the significant prognostic 
impact of such quality of life (QoL) measurements on the 
overall survival (OS) of colorectal cancer patients, and to 
demonstrate that these measures are more sensitive than 
clinician reported outcomes (CROs) in predicting mor-
tality. Of note, longer term combined analysis of patients 
in both arms of the intervention identified lower patient 
baseline outlook as associated with decreased overall 
survival.
Four RCTs were secondary analyses of chemotherapy 
interventions whereby pancreatic, bladder and gastric 
cancer patients were randomised to receive varying reg-
imens of cytotoxic therapy [15, 16, 18, 19]. Noteworthy 
observations from these studies included the prognostic 
























Additional records identified 
through other sources:
(n = 0)
Records after duplicates removed:
(n = 2167)
Records screened by 
abstract (n = 228)
Records excluded:
(n = 1939)
Full-text articles assessed 
for eligibility:
(n = 43)
Full-text articles excluded, 
with reasons:
(n =  22)
Research question/findings 
not relevant to review 
question (n = 16)
Data not specific to pelvic 
abdominal tumour types 
(n = 4)
Full text article not accessible 
(n = 2)




Articles added from 
reference lists of 
included articles:
(n = 10)
Fig. 1 PRISMA flow diagram of screening process




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 17 of 20Moss et al. Health Qual Life Outcomes           (2021) 19:20  
significance of pain and fatigue as independent indicators 
for survival in pancreatic cancer, although these meas-
ures were found to be less prognostic than the carbohy-
drate antigen 19-9 (CA-19) [15]. In addition, this study 
surmised that QoL did not predict tumour response to 
chemotherapy.
A second RCT for pancreatic cancer patients utilised 
the EORTC QLQ-C30 questionnaire to identify no sig-
nificant difference in QoL in treatment arms over time 
[16]. Subsequent multivariate analysis identified physi-
cal functioning, constipation and dyspnoea as significant 
prognostic factors in this patient cohort, with severely 
impaired physical functioning imparting the strongest 
negative effect on overall survival [16]. In the context of 
the bladder cancer RCT, Roychowdhury et  al. also uti-
lised the EORTC QLQ-C30 questionnaire to demonstrate 
physical functioning as a significant and independent 
prognosticator for time to event endpoints [19]. This 
RCT also identified a potential prognostic role for fatigue 
and anorexia in both treatment arms. Interestingly, in 
univariate analysis, higher role functioning was identified 
as a positive prognostic factor but, paradoxically, in the 
multivariate model longer overall survival was associated 
with lower role functioning.
In the setting of gastric cancer, three RCTs assess-
ing fluorouracil-based combination chemotherapy were 
combined to investigate whether pretreatment QoL pre-
dicts survival in patients with locally advanced or meta-
static disease [18]. In this study, and similarly to the other 
RCTs, better physical and role functioning predicted 
increased survival. Data was collated using the EORTC 
QLQ-C30 instrument and suggested the role of global 
QoL score as a strong prognostic factor.
In contrast to the other RCTs, a European hormo-
nal therapy/radiotherapy intervention in prostate can-
cer identified that HRQoL factors, as measured by the 
EORTC QLQ-C30 instrument, did not accurately pre-
dict overall survival once clinical and biochemical factors 
were accounted for [20]. Despite baseline global health 
status being associated with overall survival in other 
tumour types, this relationship was not demonstrated in 
this study.
Cohort studies
Full details of the 11 included cohort studies are con-
tained in Table 2. One was in the context of aggregated 
RCT data [21] and 10 were original cohorts [22–31]. The 
tumour breakdown of these patient cohorts were as fol-
lows: five analyses included urological cancer patients 
[21–23, 27, 28], four colorectal [21, 22, 30, 31], three 
gynaecological [21, 22, 26], three pancreatic [24, 25, 29] 
and one gastric cancer cohort [31].
An analysis by Jayadevappa et al. of 318 younger pros-
tate cancer patients identified that low risk biochemi-
cal recurrence is mostly indicative of better generic and 
prostate specific HRQoL [28]. Similarly, an American 
analysis of 917 prostate cancer patients demonstrated 
that patient self-rated health is a potential confounder 
in the relationship between patient satisfaction and sur-
vival; thus suggesting that future studies investigating 
patient satisfaction should include collection of self-
rated health modules [27]. In renal cancer, a study by 
Graham et al. observed that baseline use of the Edmon-
ton Symptom Assessment System provides a modest 
degree of prognostic information about survival, inde-
pendently of other widely used prognostic models [23]. 
These results were consistent with previously reported 
data examining the prognostic function of the FACT-
KSI instrument.
In pancreatic cancer patient cohorts, analyses fur-
ther suggested a role for the EORTC QLQ-C30 instru-
ment to provide prognostic information for survival 
[29]. As reported above, baseline global health was 
an independent prognosticator and, interestingly, the 
study found that the probability of survival increased 
significantly if cognitive function improved within 
three months of treatment [29]. Of note, an analysis 
of 66 Norwegian pancreatic cancer patients also dem-
onstrated that cognitive function, as measured by the 
Edmonton Symptom Scale, was an independent prog-
nostic factor [24].
In the context of colorectal cancer, a large UK study 
of 501 patients identified that patients with high base-
line global QoL have a 1-year survival that is almost 
double that of patients with a score below median value 
[30]. Multivariate analysis demonstrated that symp-
tom and functioning measures, as recorded using the 
EORTC QLQ-C30, appeared to be a stronger predictor 
of overall survival compared to clinician measured per-
formance status. A smaller analysis of 47 patients with 
advanced gastric or colorectal cancers identified that 
overall physical condition and global QoL was an inde-
pendent prognosticator of overall survival [31]. Indeed, 
further preliminary analyses demonstrated an association 
between psychological response to cancer and survival.
A Danish analysis of a gynaecological patient cohort 
investigated patient quality of life and satisfaction as 
an alternate avenue for exploring the consequences of 
diagnostic delay [26]. This study identified that, in ovar-
ian cancer patients specifically, pain was associated with 
reduced overall survival. In a subset of the cohort with 
endometrial cancer, a number of QoL domains including 
overall QoL, physical, emotional and role functioning, 
nausea and vomiting, pain, dyspnoea, and appetite loss 
were independently associated with survival [26].
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Case series
Three studies recruited prostate and pancreatic cancer 
patients consecutively [32–34]. In the context of radio-
therapy, overall survival and disease-free survival in 
prostate cancer patients with localised disease were pre-
dicted by socioeconomic status, psychological factors 
and patient self-reported QoL [32]. In this study, different 
QoL domains demonstrated favourable or unfavourable 
impact; patients with reports of few or no physical com-
plaints predicted shorter survival whereas reported pain 
was prognostic for longer overall survival.
A case series of 55 pancreatic cancer patients identi-
fied a borderline significant association between baseline 
health and physical measures and survival after adjust-
ment for disease stage at diagnosis [33]. Indeed, this 
study also suggested that patient satisfaction with QoL 
provides useful prognostic information.
Discussion
This systematic review identified several domains of 
QoL as potential prognosticators for oncological out-
comes in tumours of the pelvic abdominal cavity. Spe-
cifically, global QoL, physical and role functioning, and 
fatigue consistently emerged as independent prognostic 
factors for overall and disease-free survival across the 
included tumour types [14, 18, 19, 22, 26, 29–31, 33]. 
Other domains relating to pain, constipation, dyspnoea, 
anorexia and cognitive function also appeared to have a 
potential prognostic function, independently of the clin-
icopathological features of disease [14–16, 19, 24, 29].
Despite compelling published evidence observing 
the prognostic role of baseline QoL measurements, the 
causal relationship between QoL and overall survival 
remains enigmatic. It has previously been suggested that 
collection of self-report QoL measurements may indi-
cate the underlying severity of disease more accurately 
than other crude clinical measurements such as tumour 
burden [35]. Indeed, previously published studies have 
observed the superior nature of QoL in assessing progno-
sis compared to tumour burden; Earlam et al. successfully 
utilised physical QoL score to predict the overall sur-
vival of colorectal patients with liver metastases receiv-
ing supportive care alone and identified that the extent 
of metastasis did not influence survival [36]. In addition, 
historical studies in lung cancer [37, 38] identified QoL as 
an independent prognostic factor for survival, but failed 
to identify a significant relationship between survival and 
number of metastatic sites or disease extent. It is hypoth-
esised that tumour markers which accurately reflect 
tumour aggression may also impact patient QoL more 
significantly than tumour burden [30].
Equally, various studies have hypothesised that QoL 
may directly impact tumour behaviour and subsequent 
patient survival, although such evidence is limited and 
controversial. Various studies [39–41] suggested that 
improvements in QoL or patient mental and emotional 
wellbeing may influence survival, but were limited by 
small patient numbers. In comparison a larger study of 
more than 1000 head and neck cancer patients found 
no link between emotional wellbeing and survival in 
this patient group [42]. Overall, the potential underly-
ing mechanistic action of QoL monitoring and impact on 
patient survival requires more investigation.
Despite the evident prognostic potential of PROMs, 
our overview of the literature suggests that most PROMs 
are collected in the context of scientific research rather 
than routinely in the cancer clinical setting. Although 
it is well-established that patient perspective is an inte-
gral component of high quality and patient-centred care 
[43], financial burden and logistical issues prevent many 
healthcare systems from adopting PROM collection [10], 
and there exists a lack of uniform approach for their 
implementation in cancer specifically [11]. The PRISMA 
study, which primarily surveyed clinicians from Europe 
or Africa, highlighted physician time constraints and 
patient factors as key barriers to PROM implementation 
within the palliative care setting [44]. Additionally, a lack 
of training and guidance for clinicians were identified in 
this study as factors preventing wide-spread roll-out, and 
Gibbons et al. identified difficulties relating to budget and 
available software tools as further barriers to successful 
implementation [45].
There also exists a lack of validated tumour specific 
outcome measurement tools in cancer. Within this 
review, the majority of studies utilised baseline measure-
ments of the cancer generic EORTC QLQ-C30 instru-
ment. Although a standard tool for measuring HRQoL, 
the instrument lacks sensitivity to subtle disease specific 
changes [46]. Importance therefore lies with the devel-
opment and validation of disease specific instruments 
which can detect and quantify disease subtle changes 
and accurately inform treating clinicians and the patients 
[47].
It is also of note that this review was undertaken dur-
ing the COVID-19 pandemic when fears around the 
longer-term burden of SARS-CoV-2 on cancer care 
were emerging. During the outbreak, outpatient can-
cer care underwent a perhaps perpetual paradigm shift 
towards remote telemedicine, which further highlighted 
the necessity of routine collection of PROMs to support 
patients and allow shared clinical decision-making.
Limitations
Many of the analyses included large patient numbers 
and therefore the findings of this review can be assumed 
robust. There did, however, exist heterogeneity in the 
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study design and methodology of the included stud-
ies which ultimately prohibited a collective meta-anal-
ysis of the reported data. Ten of the included studies 
were conducted using data collated in the United States 
where private health care is prevalent, and therefore the 
results of these studies may not be generalisable across 
other populations. Equally, most of the included analy-
ses (13/21) covered pancreatic and prostate tumour types 
alone. Although the shorter and longer survival times 
associated with these cancers provide a comprehensive 
overview of quality of life across the full cancer journey, 
these cancers are analogous with a specific age range and 
the male sex. Therefore, the prognostic potential of QoL 
measures is less well understood in other tumour types 
of the pelvic abdominal cavity and may differ by sex and 
age. Further investigation into the prognostic potential of 
PROMs is warranted in such tumour types with limited 
existing evidence.
Conclusions
Overall, the findings of this review suggest a role for the 
routine collection of baseline PROMs in tumours of the 
pelvic abdominal cavity to improve both patient quality 
of life and outcomes. Specifically, global QoL, physical 
and role functioning and fatigue consistently emerged as 
independent prognosticators indicative of survival across 
these tumour types.
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